Agenus (NASDAQ:AGEN) Earns Buy Rating from Chardan Capital

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a note issued to investors on Thursday, Benzinga reports.

Several other equities research analysts have also issued reports on AGEN. HC Wainwright restated a “buy” rating and issued a $25.00 target price (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Rodman & Renshaw initiated coverage on shares of Agenus in a report on Monday, September 28th. They issued a “buy” rating and a $19.00 target price for the company. Wall Street Zen lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, August 17th. Finally, B. Riley Financial restated a “buy” rating and issued a $14.00 target price (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Agenus Stock Performance

AGEN stock traded up $0.11 during trading on Thursday, hitting $6.51. 553,852 shares of the company’s stock traded hands, compared to its average volume of 1,877,131. Agenus has a 52 week low of $2.71 and a 52 week high of $10.31. The business has a fifty day simple moving average of $7.71 and a 200 day simple moving average of $5.48. The stock has a market capitalization of $294.00 million, a price-to-earnings ratio of 2.52 and a beta of 1.31.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. The business had revenue of $34.52 million for the quarter, compared to the consensus estimate of $34.00 million. Research analysts forecast that Agenus will post -0.30 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agenus

A number of hedge funds and other institutional investors have recently modified their holdings of AGEN. Globeflex Capital L P purchased a new position in shares of Agenus in the 2nd quarter valued at $1,281,000. Bank of America Corp DE boosted its stake in Agenus by 796.7% in the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 105,536 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Agenus in the second quarter worth $311,000. Finally, Everhart Financial Group Inc. acquired a new position in shares of Agenus in the 3rd quarter valued at about $100,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.